ストックスクリーナーアプリを入手
0.5771
6.50%
-0.0401
アフターアワーズ：
.61
0.0329
+5.70%
前日終値:
$0.6172
開ける：
$0.6172
24時間の取引高:
1.04M
Relative Volume:
6.36
時価総額：
$51.77M
収益：
-
当期純損益:
$-30.15M
株価収益率:
-0.6342
EPS:
-0.91
ネットキャッシュフロー:
$-31.63M
1週間 パフォーマンス:
-16.71%
1か月 パフォーマンス:
-34.46%
6か月 パフォーマンス:
-62.03%
1年 パフォーマンス:
-71.14%
1日の値動き範囲:
$0.49
$0.6642
1週間の範囲:
$0.49
$0.71
52週間の値動き範囲:
$0.49
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
名前
Context Therapeutics Inc
セクター
電話
267-225-7416
住所
2001 MARKET STREET, PHILADELPHIA
CNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.5771 | 62.16M | 0 | -30.15M | -31.63M | -0.91 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-11-25 | 開始されました | D. Boral Capital | Buy |
| 2024-05-16 | 開始されました | Piper Sandler | Overweight |
Context Therapeutics Inc (CNTX) 最新ニュース
Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer - MyChesCo
Context Therapeutics (CNTX) Names New Chief Medical Officer | CN - GuruFocus
Context Therapeutics (CNTX) Names New Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire
Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer - Stock Titan
Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth - MSN
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts - Defense World
Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - MSN
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
William Blair Has Positive Outlook of CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX Q2 Earnings - Defense World
D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
UTR Therapeutics files IND application for UTRxM1-18 for c-MYC-driven cancers - BioWorld MedTech
Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting - MSN
Context Therapeutics (CNTX) Receives Continued 'Buy' Rating from Analyst | CNTX Stock News - GuruFocus
FORE Biotherapeutics’ Plixorafenib Study to Be Highlighted at ASCO 2025 - MyChesCo
CONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly Earnings - Nasdaq
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - GlobeNewswire
Marshall Wace LLP Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX) - The AM Reporter
Context Therapeutics Appoints Karen Smith as Interim CMO - citybiz
Context Therapeutics (CNTX) Names Karen Smith as Interim Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics appoints new interim CMO - Investing.com
Context Therapeutics appoints new interim CMO By Investing.com - Investing.com South Africa
Context Therapeutics Announces Chief Medical Officer Transition - GlobeNewswire
Context Therapeutics Inc Announces Executive Changes Effective May 10, 2025 - marketscreener.com
Renaissance Technologies LLC Boosts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World
Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World
Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World
Q1 Earnings Forecast for CNTX Issued By William Blair - Defense World
Context Therapeutics reports progress in cancer treatment By Investing.com - Investing.com India
Context Therapeutics (CNTX) Presents Promising Data on CT-95 at AACR 2025 | CNTX Stock News - GuruFocus
Context Therapeutics reports progress in cancer treatment - Investing.com
Context Therapeutics Inc. Announces Preclinical Data Supporting Unique Binding Mechanism of CT-95 and Progress in Phase 1 Clinical Trial - Nasdaq
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting - GlobeNewswire
Breakthrough Cancer Treatment CT-95 Reveals Unique Binding Mechanism in Multiple Tumor Types - Stock Titan
Q1 Earnings Estimate for CNTX Issued By William Blair - Defense World
Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - Nasdaq
Bet on These 5 Top-Ranked Stocks With Rising P/E - NewsBreak: Local News & Alerts
William Blair starts Context Therapeutics stock with Outperform By Investing.com - Investing.com Canada
Context Therapeutics Inc (CNTX) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):